Skip to content
value.today

Reviva Pharmaceuticals, Inc.

Total raised
$28 M
2 rounds on record
Latest round
$16 M
Jun 2014
First round on record
Mar 2013
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Reviva Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2014$16 MNo. 2$10 to $50 million

Reviva Pharmaceuticals, Inc.: Raise no. 2, Jun 2014

Investors in this round

47 investors had bought by the notice of Jun 25, 2014: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Conversion of Promissory Notes to Series 4 Preferred Stock
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Laxminarayan Bhat · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Laxminarayan Bhat, President & CEO. Source: SEC Form D, newest notice filed Jun 25, 2014. Read the notice at the SEC.

equitySEC
Mar 2013$12 MNo. 1$10 to $50 million

Reviva Pharmaceuticals, Inc.: Raise no. 1, Mar 2013

Investors in this round

82 investors had bought by the notice of Mar 21, 2013: 82 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: Convertible Promissory Notes and the Series 3 Preferred Stock issuable upon conversion of such notes, and the Common Stock issuable upon conversion of such Preferred Stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Laxminarayan Bhat · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Actual Total Offering Amount and Total Amount Sold is $12,039,776.65”

Signed by Laxminarayan Bhat, President and CEO. Source: SEC Form D, newest notice filed Mar 21, 2013. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Reviva Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2014).

    SEC Form D · Jun 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2014

That is all the official record says: Reviva Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Reviva Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 82 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Reviva Pharmaceuticals, Inc.
NameRoleNamed in
Laxminarayan BhatExecutive officerJun 2014
Laxminarayan BhatDirectorJun 2014